Collegium Pharmaceutical, Inc.(COLL)Earnings, Financials & Key Ratios

COLL•NASDAQ

$36.51

$1.18B mkt cap·21.1× P/E·Price updated May 6, 2026

SectorHealthcare IndustrySpecialty & Generic Pharma Sub-IndustryTherapy-focused branded biopharma

AboutCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Show more

Revenue$781M+23.6%
EBITDA$413M+21.9%
Net Income$63M-9.1%
EPS (Diluted)1.73-7.0%
Gross Margin59.35%-0.7%
EBITDA Margin52.93%-1.4%
Operating Margin23.97%-10.9%
Net Margin8.05%-26.5%
ROE23.7%-27.3%
ROIC13.97%-9.6%
Debt/Equity3.12-17.0%
Interest Coverage2.13-8.9%

Technical→

COLL Key Insights

Collegium Pharmaceutical, Inc. (COLL) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 27.0%
✓Strong 5Y profit CAGR of 18.6%
✓FCF machine: 42.0% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 20.3%

✗Weaknesses

✗High debt to equity ratio of 3.1x

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

COLL Price & Volume

Collegium Pharmaceutical, Inc. (COLL) stock price & volume — 10-year historical chart

Loading chart...

COLL Growth Metrics

Collegium Pharmaceutical, Inc. (COLL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years20.28%

3 Years18.94%

TTM23.62%

Profit CAGR

10 Years-

5 Years18.64%

3 Years-

TTM-9.13%

EPS CAGR

10 Years-

5 Years17.88%

3 Years-

TTM-7.37%

Return on Capital

10 Years-9.63%

5 Years13.55%

3 Years19.22%

Last Year15.78%

COLL Recent Earnings

Collegium Pharmaceutical, Inc. (COLL) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (50%)

Q1 2026Latest

Feb 26, 2026

EPS

$2.04

Est $2.14

-4.7%

Revenue

$205M

Est $206M

-0.4%

Q4 2025

Nov 6, 2025

EPS

$2.25

Est $1.86

+21.0%

Revenue

$209M

Est $206M

+1.6%

Q3 2025

Aug 7, 2025

EPS

$1.68

Est $1.62

+3.7%

Revenue

$188M

Est $191M

-1.7%

Q2 2025

May 8, 2025

EPS

$1.49

Est $1.43

+4.2%

Revenue

$178M

Est $173M

+2.7%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 26, 2026	$2.04vs $2.14-4.7%	$205Mvs $206M-0.4%
Q4 2025	Nov 6, 2025	$2.25vs $1.86+21.0%	$209Mvs $206M+1.6%
Q3 2025	Aug 7, 2025	$1.68vs $1.62+3.7%	$188Mvs $191M-1.7%
Q2 2025	May 8, 2025	$1.49vs $1.43+4.2%	$178Mvs $173M+2.7%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
AVDLAvadel Pharmaceuticals plcDirect Competitor	2.1B	21.64	-42.43	5.05%	-0.11%	-0.33%	0.02
HRMYHarmony Biosciences Holdings, Inc.Direct Competitor	1.89B	32.78	12.10	21.51%	18.27%	18.24%	0.02
SUPNSupernus Pharmaceuticals, Inc.Direct Competitor	2.96B	51.45	-75.66	8.63%	-3.74%	-2.73%	0.04
PCRXPacira BioSciences, Inc.Product Competitor	931.85M	23.69	148.06	3.63%	1.27%	1.31%	0.66
PRGOPerrigo Company plcProduct Competitor	1.69B	12.26	-1.19	-2.75%	-43.5%	-50.65%	1.35
MCKMcKesson CorporationSupply Chain	91.09B	743.67	28.91	16.22%	1.09%
CAHCardinal Health, Inc.Supply Chain	45.06B	191.49	29.69	-1.87%	0.62%
CVSCVS Health CorporationSupply Chain	111.32B	86.86	62.49	7.85%	0.72%	3.86%	1.24

Compare COLL vs Peers

Collegium Pharmaceutical, Inc. (COLL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs AVDL

Most directly comparable listed peer for COLL.

Scale Benchmark

vs CVS

Larger-name benchmark to compare COLL against a more recognizable public peer.

Peer Set

Compare Top 5

vs AVDL, HRMY, SUPN, PCRX

COLL Income Statement

Collegium Pharmaceutical, Inc. (COLL) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	28.48M	280.41M	296.7M	310.02M	276.87M	463.93M	566.77M	631.45M	780.57M
Revenue Growth %	1564.29%	884.73%	5.81%	4.49%	-10.69%	67.56%	22.17%	11.41%	23.62%
Cost of Goods Sold	2.6M	165.68M	193.66M	130.18M	126.25M	254.44M	240.6M	254.1M	317.31M
COGS % of Revenue	9.11%	59.08%	65.27%	41.99%	45.6%	54.85%	42.45%	40.24%	40.65%
Gross Profit	25.88M▲ 0%	114.74M▲ 343.3%	103.04M▼ 10.2%	179.84M▲ 74.5%	150.62M▼ 16.2%	209.49M▲ 39.1%	326.17M▲ 55.7%	377.34M▲ 15.7%	463.26M▲ 22.8%
Gross Margin %	90.89%	40.92%	34.73%	58.01%	54.4%	45.15%	57.55%	59.76%	59.35%
Gross Profit Growth %	1627.7%	343.32%	-10.19%	74.53%	-16.25%	39.09%	55.7%	15.69%	22.77%
Operating Expenses	101.33M	135.42M	126.79M	123.6M	132.99M	176.17M	159.21M	207.45M	276.17M
OpEx % of Revenue	355.84%	48.29%	42.73%	39.87%	48.03%	37.97%	28.09%	32.85%	35.38%
Selling, General & Admin	92.76M	126.76M	116.45M	113.83M	118.96M	172.19M	159.21M	182.98M	276.17M
SG&A % of Revenue	325.73%	45.2%	39.25%	36.72%	42.97%	37.11%	28.09%	28.98%	35.38%
Research & Development	8.57M	8.66M	10.34M	9.77M	9.45M	3.98M	0	0	0
R&D % of Revenue	30.1%	3.09%	3.48%	3.15%	3.41%	0.86%	-	-	-
Other Operating Expenses	0	0	0	0	4.58M	0	0	24.47M	0
Operating Income	-75.45M▲ 0%	-20.68M▲ 72.6%	-23.75M▼ 14.8%	56.23M▲ 336.8%	17.63M▼ 68.7%	33.32M▲ 89.0%	166.96M▲ 401.1%	169.9M▲ 1.8%	187.08M▲ 10.1%
Operating Margin %	-264.95%	-7.38%	-8%	18.14%	6.37%	7.18%	29.46%	26.91%	23.97%
Operating Income Growth %	19.81%	72.58%	-14.81%	336.79%	-68.65%	89.01%	401.1%	1.76%	10.12%
EBITDA	-74.85M	90.22M	-8.27M	117.78M	86.55M	172.26M	316.22M	339.06M	413.16M
EBITDA Margin %	-262.86%	32.17%	-2.79%	37.99%	31.26%	37.13%	55.79%	53.69%	52.93%
EBITDA Growth %	19.88%	220.53%	-109.16%	1525.07%	-26.52%	99.04%	83.57%	7.22%	21.86%
D&A (Non-Cash Add-back)	594K	110.91M	15.48M	61.55M	68.92M	138.94M	149.26M	169.16M	226.07M
EBIT	-74.86M	-19M	-21.81M	56.46M	17.64M	34.37M	159.07M	172.54M	174.93M
Net Interest Income	582K	-18.44M	1.03M	-28.65M	-21M	-62.17M	-67.72M	-60M	-71.02M
Interest Income	582K	1.69M	1.94M	232K	12K	1.05M	15.62M	13.98M	11.29M
Interest Expense	0	20.13M	909K	28.88M	21.01M	63.21M	83.34M	73.97M	82.31M
Other Income/Expense	582K	-18.44M	1.03M	-28.65M	-21M	-62.17M	-91.23M	-71.33M	-94.47M
Pretax Income	-74.86M▲ 0%	-39.13M▲ 47.7%	-22.72M▲ 41.9%	27.58M▲ 221.4%	-3.37M▼ 112.2%	-28.85M▼ 755.0%	75.73M▲ 362.5%	98.57M▲ 30.2%	92.62M▼ 6.0%
Pretax Margin %	-262.91%	-13.95%	-7.66%	8.9%	-1.22%	-6.22%	13.36%	15.61%	11.87%
Income Tax	0	0	0	830K	-74.89M	-3.85M	27.58M	29.38M	29.75M
Effective Tax Rate %	0%	0%	0%	3.01%	2219.65%	13.33%	36.41%	29.8%	32.12%
Net Income	-74.86M▲ 0%	-39.13M▲ 47.7%	-22.72M▲ 41.9%	26.75M▲ 217.7%	71.52M▲ 167.3%	-25M▼ 135.0%	48.16M▲ 292.6%	69.19M▲ 43.7%	62.87M▼ 9.1%
Net Margin %	-262.91%	-13.95%	-7.66%	8.63%	25.83%	-5.39%	8.5%	10.96%	8.05%
Net Income Growth %	20.51%	47.74%	41.93%	217.74%	167.33%	-134.96%	292.6%	43.68%	-9.13%
Net Income (Continuing)	-74.86M	-39.13M	-22.72M	26.75M	71.52M	-25M	48.16M	69.19M	62.87M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-2.47▲ 0%	-1.19▲ 51.8%	-0.24▲ 79.8%	0.76▲ 416.7%	1.86▲ 144.7%	-0.74▼ 139.8%	1.29▲ 274.3%	1.86▲ 44.2%	1.73▼ 7.0%
EPS Growth %	36.34%	51.82%	79.83%	416.67%	144.74%	-139.78%	274.32%	44.19%	-6.99%
EPS (Basic)	-2.47	-1.19	-0.24	0.78	2.05	-0.74	1.60	2.14	1.98
Diluted Shares Outstanding	30.27M	32.95M	33.45M	35.15M	41.05M	33.83M	41.79M	40.42M	39.7M
Basic Shares Outstanding	30.27M	32.88M	33.45M	34.41M	34.94M	33.83M	33.74M	32.27M	31.71M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

COLL Balance Sheet

Collegium Pharmaceutical, Inc. (COLL) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	133.48M	237.51M	255.72M	277.89M	315.54M	419.99M	537.6M	482.26M	691.41M
Cash & Short-Term Investments	118.7M	146.63M	170.02M	174.12M	186.43M	173.69M	310.55M	162.76M	406.53M
Cash Only	118.7M	146.63M	170.02M	174.12M	186.43M	173.69M	238.95M	70.56M	251.1M
Short-Term Investments	0	0	0	0	0	0	71.6M	92.2M	155.43M
Accounts Receivable	9.97M	77.95M	72.95M	83.32M	105.84M	183.12M	179.53M	228.54M	211.33M
Days Sales Outstanding	127.78	101.46	89.75	98.1	139.54	144.07	115.61	132.1	98.82
Inventory	1.81M	7.82M	9.64M	15.61M	17.39M	46.5M	32.33M	35.56M	40.91M
Days Inventory Outstanding	255.01	17.22	18.17	43.78	50.29	66.71	49.05	51.08	47.06
Other Current Assets	456K	1.01M	141K	60K	27K	57K	93K	27.74M	3.24M
Total Non-Current Assets	2.08M	53.73M	50.58M	365.95M	376.53M	754.14M	605.71M	1.18B	965.42M
Property, Plant & Equipment	1.83M	9.27M	20.9M	27.38M	27.14M	26.38M	22.01M	20.15M	16.2M
Fixed Asset Turnover	15.59x	30.24x	14.20x	11.32x	10.20x	17.59x	25.75x	31.34x	48.18x
Goodwill	0	0	0	0	0	133.69M	133.86M	162.33M	145.93M
Intangible Assets	0	44.26M	29.5M	335.9M	268.72M	567.47M	421.71M	891.4M	669.51M
Long-Term Investments	97K	0	0	0	0	0	0	0	1.06M
Other Non-Current Assets	161K	204K	178K	2.67M	2.63M	2.65M	1.87M	9.41M	20.19M
Total Assets	135.57M▲ 0%	291.25M▲ 114.8%	306.3M▲ 5.2%	643.84M▲ 110.2%	692.08M▲ 7.5%	1.17B▲ 69.7%	1.14B▼ 2.6%	1.66B▲ 45.5%	1.66B▼ 0.4%
Asset Turnover	0.21x	0.96x	0.97x	0.48x	0.40x	0.40x	0.50x	0.38x	0.47x
Asset Growth %	-16.32%	114.83%	5.17%	110.2%	7.49%	69.65%	-2.63%	45.51%	-0.41%
Total Current Liabilities	31.49M	187.48M	201.76M	239.45M	279.57M	433.73M	457.92M	509.51M	440.03M
Accounts Payable	5.68M	12.15M	6.25M	10.02M	4.19M	3.49M	8.69M	3.93M	10.66M
Days Payables Outstanding	799.48	26.77	11.77	28.08	12.11	5.01	13.19	5.65	12.26
Short-Term Debt	1.48M	1.64M	3.83M	47.49M	48.35M	162.5M	183.33M	64.58M	30.41M
Deferred Revenue (Current)	0	0	0	0	0	0	988K	0	667K
Other Current Liabilities	18.21M	167.7M	5.7M	1.42M	851K	1.51M	253.91M	7.61M	378.73M
Current Ratio	4.24x	1.27x	1.27x	1.16x	1.13x	0.97x	1.17x	0.95x	1.57x
Quick Ratio	4.18x	1.23x	1.22x	1.10x	1.07x	0.86x	1.10x	0.88x	1.48x
Cash Conversion Cycle	-416.7	91.91	96.15	113.79	177.71	205.76	151.48	177.53	133.62
Total Non-Current Liabilities	7.16M	12.18M	17.11M	218.36M	209.58M	545.56M	489.96M	925.24M	915.13M
Long-Term Debt	0	9.86M	7.67M	209.59M	201.63M	538.45M	483.84M	787.9M	906.02M
Capital Lease Obligations	0	0	9.44M	8.77M	7.95M	7.11M	6.12M	5.54M	4.13M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	676K	0	0	0	0	0	121.8M	-4.13M
Total Liabilities	31.49M	199.66M	218.87M	457.81M	489.15M	979.29M	947.88M	1.43B	1.36B
Total Debt	1.48M	11.5M	21.59M	266.58M	258.75M	709.17M	674.28M	859.3M	940.56M
Net Debt	-117.22M	-135.13M	-148.43M	92.47M	72.32M	535.49M	435.34M	788.73M	689.46M
Debt / Equity	0.01x	0.13x	0.25x	1.43x	1.28x	3.64x	3.45x	3.75x	3.12x
Debt / EBITDA	-	0.13x	-	2.26x	2.99x	4.12x	2.13x	2.53x	2.28x
Net Debt / EBITDA	-	-1.50x	-	0.79x	0.84x	3.11x	1.38x	2.33x	1.67x
Interest Coverage	-	-0.94x	-24.00x	1.95x	0.84x	0.54x	1.91x	2.33x	2.13x
Total Equity	104.08M▲ 0%	91.58M▼ 12.0%	87.43M▼ 4.5%	186.03M▲ 112.8%	202.93M▲ 9.1%	194.84M▼ 4.0%	195.43M▲ 0.3%	228.84M▲ 17.1%	301.68M▲ 31.8%
Equity Growth %	-22.85%	-12.01%	-4.53%	112.77%	9.08%	-3.98%	0.3%	17.1%	31.83%
Book Value per Share	3.44	2.78	2.61	5.29	4.94	5.76	4.68	5.66	7.60
Total Shareholders' Equity	104.08M	91.58M	87.43M	186.03M	202.93M	194.84M	195.43M	228.84M	301.68M
Common Stock	33K	33K	34K	35K	36K	37K	38K	40K	41K
Retained Earnings	-298.05M	-337.18M	-359.9M	-333.15M	-256.34M	-281.34M	-233.19M	-164M	-101.13M
Treasury Stock	0	0	0	0	-42.86M	-61.92M	-137.38M	-197.5M	-222.51M
Accumulated OCI	-1.67M	0	0	0	0	0	14K	55K	319K
Minority Interest	0	0	0	0	0	0	0	0	0

COLL Cash Flow Statement

Collegium Pharmaceutical, Inc. (COLL) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	-67.02M	169.39M	27.78M	93.94M	103.56M	124.23M	274.75M	204.98M	329.32M
Operating CF Margin %	-235.35%	60.41%	9.36%	30.3%	37.4%	26.78%	48.48%	32.46%	42.19%
Operating CF Growth %	10.71%	352.75%	-83.6%	238.13%	10.23%	19.96%	121.16%	-25.39%	60.66%
Net Income	-74.86M	-39.13M	-22.72M	26.75M	71.52M	-25M	48.16M	69.19M	62.87M
Depreciation & Amortization	594K	110.91M	15.48M	61.55M	68.92M	138.94M	149.26M	169.16M	220.82M
Stock-Based Compensation	7.95M	13.78M	16.53M	21.91M	24.25M	22.87M	27.14M	32.4M	41.91M
Deferred Taxes	1.84M	0	0	0	-78.04M	-8.39M	-2.15M	-26.81M	-25.66M
Other Non-Cash Items	-34K	19.28M	-5.59M	9.03M	3.42M	8.52M	30.62M	16.02M	25.62M
Working Capital Changes	-2.5M	64.55M	24.08M	-25.3M	13.49M	-12.71M	21.73M	-54.98M	3.76M
Change in Receivables	-7.84M	-68.23M	4.99M	-10.37M	-22.52M	-21.78M	3.59M	-4.41M	17.2M
Change in Inventory	-497K	219K	-1.83M	-8.27M	-2.3M	48.27M	14.17M	13.93M	-5.35M
Change in Payables	-3.42M	6.46M	0	3.77M	-5.83M	-707K	5.06M	-11.28M	6.72M
Cash from Investing	-990K	-24.35M	-6.44M	-373.77M	-1.94M	-573.69M	-70.81M	-287.76M	-63.53M
Capital Expenditures	-990K	-24.35M	-6.44M	-5.55M	-1.94M	-1.62M	-461K	-1.65M	-1.74M
CapEx % of Revenue	3.48%	8.69%	2.17%	1.79%	0.7%	0.35%	0.08%	0.26%	0.22%
Acquisitions	0	0	0	0	0	-572.07M	0	-267.54M	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	-18.88M	0	-368.23M	0	0	0	0	0
Cash from Financing	33.48M	-117.2M	2.04M	286.47M	-89.3M	436.72M	-140.18M	-60.6M	-110.25M
Debt Issued (Net)	-2.67M	10.02M	0	281.39M	-50M	442.68M	-65.92M	7.52M	-70.38M
Equity Issued (Net)	34.34M	-30K	-822K	0	-47.86M	-14.06M	-75M	-60.02M	-19.46M
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	-560K	-822K	0	-47.86M	-14.06M	-75M	-60.02M	-25.1M
Other Financing	1.81M	-127.19M	2.86M	5.08M	8.56M	8.1M	740K	-8.1M	-20.4M
Net Change in Cash	-34.53M▲ 0%	27.84M▲ 180.6%	23.39M▼ 16.0%	6.64M▼ 71.6%	12.31M▲ 85.3%	-12.74M▼ 203.5%	63.76M▲ 600.5%	-143.38M▼ 324.9%	155.55M▲ 208.5%
Free Cash Flow	-68.01M▲ 0%	145.04M▲ 313.3%	21.34M▼ 85.3%	-279.83M▼ 1411.0%	101.61M▲ 136.3%	122.61M▲ 20.7%	274.29M▲ 123.7%	203.33M▼ 25.9%	327.58M▲ 61.1%
FCF Margin %	-238.83%	51.72%	7.19%	-90.26%	36.7%	26.43%	48.4%	32.2%	41.97%
FCF Growth %	12.84%	313.26%	-85.28%	-1410.99%	136.31%	20.66%	123.71%	-25.87%	61.11%
FCF per Share	-2.25	4.40	0.64	-7.96	2.48	3.62	6.56	5.03	8.25
FCF Conversion (FCF/Net Income)	0.90x	-4.33x	-1.22x	3.51x	1.45x	-4.97x	5.71x	2.96x	5.24x
Interest Paid	0	0	709K	18.97M	17.61M	52.53M	73.26M	62.43M	0
Taxes Paid	0	0	0	483K	3M	10.4M	24.2M	52.09M	0

COLL Key Ratios

Collegium Pharmaceutical, Inc. (COLL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-85.62%	-62.65%	-39.99%	-25.39%	19.57%	36.77%	-12.57%	24.68%	32.62%	23.7%
Return on Invested Capital (ROIC)	-	-	-	-	38.78%	4.78%	4.97%	18.4%	15.46%	13.97%
Gross Margin	87.55%	90.89%	40.92%	34.73%	58.01%	54.4%	45.15%	57.55%	59.76%	59.35%
Net Margin	-5504.15%	-262.91%	-13.95%	-7.66%	8.63%	25.83%	-5.39%	8.5%	10.96%	8.05%
Debt / Equity	0.03x	0.01x	0.13x	0.25x	1.43x	1.28x	3.64x	3.45x	3.75x	3.12x
Interest Coverage	-1000.87x	-	-0.94x	-24.00x	1.95x	0.84x	0.54x	1.91x	2.33x	2.13x
FCF Conversion	0.80x	0.90x	-4.33x	-1.22x	3.51x	1.45x	-4.97x	5.71x	2.96x	5.24x
Revenue Growth	-	1564.29%	884.73%	5.81%	4.49%	-10.69%	67.56%	22.17%	11.41%	23.62%

COLL SEC Filings & Documents

Collegium Pharmaceutical, Inc. (COLL) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 7, 2026·SEC

Material company update

Mar 19, 2026·SEC

Material company update

Feb 26, 2026·SEC

10-K Annual Reports

FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 22, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

FY 2025

May 8, 2025·SEC

COLL Frequently Asked Questions

Collegium Pharmaceutical, Inc. (COLL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Collegium Pharmaceutical, Inc. (COLL) reported $780.6M in revenue for fiscal year 2025.

Collegium Pharmaceutical, Inc. (COLL) grew revenue by 23.6% over the past year. This is strong growth.

Yes, Collegium Pharmaceutical, Inc. (COLL) is profitable, generating $62.9M in net income for fiscal year 2025 (8.1% net margin).

Dividend & Returns

Collegium Pharmaceutical, Inc. (COLL) has a return on equity (ROE) of 23.7%. This is excellent, indicating efficient use of shareholder capital.

Collegium Pharmaceutical, Inc. (COLL) generated $327.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More COLL

Collegium Pharmaceutical, Inc. (COLL) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Collegium Pharmaceutical, Inc.(COLL)Earnings, Financials & Key Ratios

COLL Key Insights

✓Strengths

✗Weaknesses

COLL Price & Volume

COLL Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

COLL Recent Earnings

COLL Peer Comparison

Compare COLL vs Peers

vs AVDL

vs CVS

Compare Top 5

COLL Income Statement

COLL Balance Sheet

COLL Cash Flow Statement

COLL Key Ratios

COLL SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

COLL Frequently Asked Questions

Explore More COLL

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation